SOPHiA GENETICS SA (SOPH), a health technology firm focused on data-driven precision medicine, announced on Monday an expansion of its partnership with AstraZeneca PLC (AZN).
Through this partnership, the companies intend to improve the diagnosis and treatment of breast and prostate cancers by developing an optimized next-generation sequencing (NGS) solution that utilizes SOPHiA GENETICS' AI-driven algorithms.
As part of the deal, SOPHiA GENETICS will introduce a Privileged Access Program for select breast and prostate cancer laboratories to validate performance in real-world settings, with full commercial rollout anticipated in 2026 alongside a multi-center real-world evidence study.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.